Clinical Trial Detail

NCT ID NCT03131908
Title Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

melanoma

Therapies

GSK2636771 + Pembrolizumab

Age Groups: senior adult

No variant requirements are available.